SubHero Banner

Columvi® (glofitamab-gxbm) – New drug approval

June 16, 2023 - Roche announced the FDA approval of Columvi (glofitamab-gxbm), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.

Download PDF